- GlobeNewswire•3 days ago
Securities Class Action Lawsuit lacked any valid basis and was voluntarily dismissed. NEW YORK and CLEVELAND, Feb. 23, 2017-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company ...
- GlobeNewswire•5 days agoAbeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
Company CEO and COO Presentations to be Held on Wednesday, February 22nd. NEW YORK and CLEVELAND, Feb. 21, 2017-- Abeona Therapeutics Inc. a leading clinical-stage biopharmaceutical company focused on ...
- GlobeNewswire•9 days agoAbeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
NEW YORK and CLEVELAND, Feb. 17, 2017-- Abeona Therapeutics Inc.:. ABO-102 gene therapy well-tolerated in 4 subjects through 650 days follow up with no Serious Adverse Events 63%+/- 0.5% central nervous ...
ABEO : Summary for Abeona Therapeutics Inc. - Yahoo Finance
Abeona Therapeutics Inc. (ABEO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.00 x 2000|
|Ask||6.00 x 1000|
|Day's Range||4.90 - 5.25|
|52 Week Range||2.05 - 9.44|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-10.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|